Stock Market

AstraZeneca will buy oncology firm TeneoTwo for up to $1.27 billion.

(Reuters) – AstraZeneca (NASDAQ:AZN) stated on Tuesday it will purchase oncology business TeneoTwo Inc in a deal valued at up to $1.27 billion, including the company’s first-stage T-cell engager.

The London-listed drugmaker wants to buy all outstanding equity of TeneoTwo for an upfront payment of $100 million on deal closing.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button